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Peritonitis rates with
biocompatible and conventional
peritoneal dialysis solutions
To the Editor: I have read with interest the study by
Srivastava et al.1 reporting no difference in peritonitis rates
and technique survival in patients randomized to biocompa-
tible or conventional peritoneal dialysis (PD) solutions.
However, PD-related peritonitis is not the only cause of PD
technique dropout, and the data provided do not fully clarify
whether the PD technique survival rates in ﬁgures 1 and 2 were
calculated only with regard to dropouts due to resistant-to-
therapy PD peritonitis, or whether other reasons such as PD
catheter malfunction, leaking, etc., were also included.
The study also reports a rather high rate of culture-negative
peritonitis episodes (23.7%) that exceeds the suggested upper
threshold of the International Society for Peritoneal Dialysis
recommendations.2
It is also well established that not all PD-related peritonitis
episodes are of equal clinical signiﬁcance. With regard to Gram-
positive microorganisms, coagulase-negative Staphylococci have
usually a more favorable outcome, whereas Staphylococcus
aureus or Enterococcus species may lead to resistant-to-therapy
peritonitis and a need for PD catheter removal. The same may
also apply for Gram-negative microorganisms such as Pseudo-
monas species and deﬁnitely for fungal peritonitis.2 It is
noteworthy that there were three cases of fungal peritonitis in
the conventional PD solutions group but only one in the
biocompatible group. Thus, an analysis of the exact incidence of
dropouts due to peritonitis only is warranted before reaching
the deﬁnite conclusion that there is no clinical difference
regarding peritonitis between these solutions.
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The Authors Reply: Prof. Fourtounas1 raised some pertinent
issues about the importance of selecting appropriate end points
for a study that compares ‘biocompatible’ peritoneal dialysis
(PD) solutions against their ‘standard’ counterpart.
We did not compare PD technique survival between the
two groups with the outcome censored for all ‘noninfective’
causes of change of modality.2 It is true that modality changes
caused by PD catheter malfunction and leaks are unlikely to
be related to the type of PD solution. Thus, our choice of end
point is associated with increased ‘noise’ and reduced the
chance that a statistically signiﬁcant outcome related to the
use of biocompatible PD solution would be found. Never-
theless, we believe that our primary end points were the most
clinically relevant. Moreover, it is our policy to continually
perform risk assessments on PD patients, and frequent peritonitis
may have precipitated an elective switch to hemodialysis. If
the primary end point only included patients with PD peritonitis
resistant to treatment, we would not include these ‘elective
switch’ patients. We must also remember that our study was
not and could not be blinded, and thus hard end points were
essential. For these reasons, we deﬁned PD technique failure
as any cause of transfer to hemodialysis (censored for
transplantation, transfer out of unit þ / death).
Should we have performed a sub-analysis examining the
peritonitis rate caused by ‘virulent’ organisms (Staphylococcus
aureus, Enterococci, Gram-negative bacteria, including Pseu-
domonas, and fungi)? In fact, I would suggest that the beneﬁt
of improved neutrophil function is most likely to be demon-
strated by reduced infections from low virulent bacteria; i.e., it
would not have been logical to have prespeciﬁed infection
rates from ‘virulent’ organisms as a primary end point.
Pre-specifying peritonitis caused by speciﬁc organisms as
an end point for our study would have reduced the power of
the study. Our ‘virulent’ organism peritonitis rate was 0.118
episodes per patient-year. Even with over 250 patient-years of
follow-up in each group, our study would only be powered to
detect a 450% reduction in infection rate (type I error 0.05,
type II error 80%)—we would not realistically expect such a
marked reduction of infections from Pseudomonas, Candida,
etc., through the use of biocompatible PD solutions.
By noting a small (nonsigniﬁcant) difference in fungal
peritonitis rate and going on to compare the infection rate
caused by ‘high virulent’ organism is to risk the accusation of
‘data trawling’. Nevertheless, we have looked at our data as
Table 1 | Peritonitis rate of patient treated with biocompatible vs. standard peritoneal dialysis (PD) solutions with particular
emphasis on ‘virulent’ pathogens
Peritonitis (absolute number/rate per patient-year)
PD solution
Months on
treatment
Total
number
Staphylococcus
aureus
Enterococcus
and Gram
negative Pseudomonas Fungal
Combined
‘virulent’
organisms
Standard 3465 110.00 5 (0.017) 22 (0.076) 3 (0.010) 4 (0.014) 34 (0.118)
Biocompatible 3943 117.00 2 (0.061) 19 (0.058) 7 (0.021) 2 (0.061) 30 (0.091)
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